SOX2 and cancer: By multivariate survival analysis, Sox2 was a robust pejorative prognostic factor (HR = 1.48, 95% CI 1.04–2.11, p = 0.0292), independent of cancer stage at diagnosis, and independent of AR, whose prognostic value was favorable (p < 0.0001 for the model, Table 3).